Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chromosome 17 deletion × Dexamethasone × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 108 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Recurrence 15 Burkitt Lymphoma 11 Neoplasms, Plasma Cell 8 Immunoglobulin Light-chain Amyloidosis 8 Neoplasms 7 Prostatic Neoplasms 6 Neoplasm Metastasis 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasm, Residual 4 Lung Neoplasms 4 Leukemia, Biphenotypic, Acute 4 Carcinoma, Non-Small-Cell Lung 4 Paraproteinemias 3 Lymphoma, Mantle-Cell 3 Lymphoma, B-Cell 3 Lymphoma 3 Leukemia 3 Breast Neoplasms 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Renal Insufficiency 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Hodgkin Disease 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2

Interventions

venetoclax 1 pomalidomide 1 pembrolizumab 1 ibrutinib 1 fludarabine phosphate 1 fludarabine 1 acalabrutinib 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01745640 2026-02-05

IFM2010-02

University Hospital, Lille

Phase 2 Completed

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡